63.29
0.87%
+0.5468
Invesco Biotechnology & Genome ETF stock is currently priced at $63.29, with a 24-hour trading volume of 5,660.
It has seen a +0.87% increased in the last 24 hours and a +3.98% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $62.58 pivot point. If it approaches the $63.62 resistance level, significant changes may occur.
Previous Close:
$62.75
Open:
$63.13
24h Volume:
5,660
Market Cap:
$281.93M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-0.74%
1M Performance:
+3.98%
6M Performance:
+8.01%
1Y Performance:
+4.97%
Invesco Biotechnology & Genome ETF Stock (PBE) Company Profile
Name
Invesco Biotechnology & Genome ETF
Sector
Industry
Phone
800-983-0903
Address
-
Invesco Biotechnology & Genome ETF Stock (PBE) Latest News
1321927 Shares in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Acquired by Norges Bank - Defense World
Defense World
Innoviva, Inc. (NASDAQ:INVA) Shares Sold by Teacher Retirement System of Texas - Defense World
Defense World
Biotech ETFs in Focus on Covid Vaccines' Fall Rollout - Yahoo News UK
Yahoo News UK
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? - Yahoo Movies UK
Yahoo Movies UK
Bio-Rad Laboratories, Inc. (NYSE:BIO) Position Lowered by Janney Montgomery Scott LLC - Defense World
Defense World
Assetmark Inc. Purchases 2184 Shares of Innoviva, Inc. (NASDAQ:INVA) - Defense World
Defense World
Invesco Biotechnology & Genome ETF Stock (PBE) Financials Data
There is no financial data for Invesco Biotechnology & Genome ETF (PBE). Check out other stocks for more information.
About Invesco Biotechnology & Genome ETF
The investment seeks to track the investment results (before fees and expenses) of the Dynamic Biotech & Genome IntellidexSM Index.
The fund generally will invest at least 90% of its total assets in common stocks of biotechnology companies and genome companies that comprise the underlying intellidex. The underlying intellidex was composed of common stocks of 30 U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified.
Cap:
|
Volume (24h):